Nuvation BioNUVB.WS 33 OCF Yield % is -5.59 as of Jun. 25, 2026. GuruFocus rates NUVB.WS with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Nuvation Bio ranks better than 57.36% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nuvation Bio OCF Yield % Related Terms
Nuvation Bio OCF Yield % Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUVB.WS vs GLUE, ATAI, BHVN: OCF Yield % Comparison
For the Biotechnology subindustry, Nuvation Bio's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB.WS) has a OCF Yield % of -5.59 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Nuvation Bio and its competitors. According to the industry distribution chart, Nuvation Bio ranks #605 out of 1419 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Nuvation Bio's OCF Yield % too high?
Nuvation Bio's current OCF Yield % is -5.59. Based on the distribution chart, Nuvation Bio ranks #605 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's OCF Yield % compare to GLUE and ATAI?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #605 out of 1419 companies for OCF Yield %. This puts Nuvation Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Nuvation Bio and its competitors. Nuvation Bio's current OCF Yield % is -5.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB.WS) has a current OCF Yield % of -5.59. The current OCF Yield % is -5.59. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Nuvation Bio (NUVB.WS), the current OCF Yield % is -5.59 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB.WS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB.WS has been successfully added to your 
